Myriad Genetics, Inc. (MYGN) recently announced a joint effort with Ultima Genomics, Inc. to explore its UG 100 sequencing platform and ppmSeq technology. The collaboration will help advance the company’s ability to offer groundbreaking clinical tests in oncology and reproductive genomics.Myriad Genetics has purchased a new UG 100 platform that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco. The low-cost, low-error sequencing achievable on the ...